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Abstract 
Indolent T-cell lymphoproliferative disorders of the gastrointestinal tract are rare clonal 
T-cell diseases that more commonly occur in the intestines and have a protracted 
clinical course. Different immunophenotypic subsets have been described, but the 
molecular pathogenesis and cell of origin of these lymphocytic proliferations is poorly 
understood. Hence, we performed targeted next-generation sequencing and 
comprehensive immunophenotypic analysis of 10 indolent T-cell lymphoproliferative 
disorders of the gastrointestinal tract, which comprised CD4+ (n=4), CD8+ (n=4), 
CD4+/CD8+ (n=1) and CD4-/CD8- (n=1) cases. Genetic alterations, including recurrent 
mutations and novel rearrangements, were identified in 8/10 (80%) lymphoproliferative 
disorders. The CD4+, CD4+/CD8+, and CD4-/CD8- cases harbored frequent alterations 
of the JAK-STAT pathway genes (5/6, 82%); STAT3 mutations (n=3), SOCS1 deletion 
(n=1) and STAT3-JAK2 rearrangement (n=1), and 4/6 (67%) had concomitant mutations 
in epigenetic modifier genes (TET2, DNMT3A, KMT2D). Conversely, 2/4 (50%) of the 
CD8+ cases exhibited structural alterations involving the 3’ untranslated region of the 
IL2 gene. Longitudinal genetic analysis revealed stable mutational profiles in 4/5 (80%) 
cases and acquisition of mutations in one case were a harbinger of disease 
transformation. The CD4+ and CD4+/CD8+ lymphoproliferative disorders displayed 
heterogeneous Th1 (T-bet+), Th2 (GATA3+) or hybrid Th1/Th2 (T-bet+/GATA3+) 
profiles, while the majority of CD8+ disorders and the CD4-/CD8- disease showed a 
type-2 polarized (GATA3+) effector T-cell (Tc2) phenotype. Additionally, CD103 
expression was noted in 2/4 CD8+ cases. Our findings provide insights into the 
pathogenetic bases of indolent T-cell lymphoproliferative disorders of the 
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gastrointestinal tract and confirm the heterogeneous nature of these diseases. 
Detection of shared and distinct genetic alterations of the JAK-STAT pathway in certain 
immunophenotypic subsets warrants further mechanistic studies to determine whether 
therapeutic targeting of this signaling cascade is efficacious for a proportion of patients 
with these recalcitrant diseases.  
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Introduction 
Non-Hodgkin lymphomas frequently occur in the gastrointestinal (GI) tract, with the 
majority representing  B-cell neoplasms1–3. T-cell lymphomas account for 10-20% of all 
primary GI lymphomas1–3. Aggressive lymphomas, including enteropathy-associated T-
cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma 
(MEITL), are among the more common types of primary GI T-cell lymphomas, which are 
associated with high morbidity and mortality1,4,5. In recent years, there has been a 
growing awareness of indolent T- and NK-cell lymphoproliferative disorders that can 
also arise within the GI tract and involve a variety of GI organs6,7. The pathogenesis of 
indolent NK-cell disorders is unclear and it is not yet known if they constitute neoplastic 
proliferations of NK-cells7. Indolent T-cell lymphoproliferative disorders (ITLPDs) of the 
GI tract, which constitute an immunophenotypically diverse group of clonal T-cell 
diseases, have been better characterized and hence included as provisional entities in 
the revised 4th edition of the World Health Organization (WHO) classification of 
lymphoid neoplasms1. The clinical, morphological, and immunophenotypic features of 
ITLPDs of the GI tract differ from other types of primary GI T-cell lymphomas6,8–16 and 
their cellular derivation, although not well established, is also considered to be 
distinct9,11. Overlapping genomic and genetic alterations have been reported in EATL 
and MEITL17–21. Limited data suggest a different spectrum of genomic aberrations in 
ITLPDs of the GI tract11,13, and until recently, no recurrent genetic abnormality had been 
identified in these disorders15. However, the mutational landscape and molecular 
pathways underlying the initiation and progression of ITLPDs of the GI tract are 
unknown and the cell of origin of the different immunophenotypic subsets has not been 
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defined. To gain further insights into the biology of these rare diseases, we performed 
comprehensive immunohistochemical, molecular and targeted next-generation 
sequencing analyses of a series of 10 cases. 
 
Methods 
Case selection 
The pathology department databases of multiple institutions were searched for primary 
gastrointestinal T-cell lymphomas, over a 23 year period (1996-2018), to identify cases 
fulfilling histopathologic and clinical criteria of ITLPDs as defined in the revised WHO 
classification1. Clinical data, including therapy and outcomes, were obtained from the 
treating physicians or electronic medical records. The study was performed in 
accordance with the principles of the Declaration of Helsinki and protocols approved by 
the Institutional Review Boards of the participating institutions. 
 
Morphology and immunophenotypic analysis 
Hematoxylin and Eosin (H&E) stained formalin-fixed, paraffin-embedded (FFPE) biopsy 
sections were reviewed to assess cyto-architectural features. Immunohistochemical 
staining was performed using a comprehensive panel of antibodies, including those 
directed against T-cell antigens, lineage associated transcription factors, immune 
checkpoint molecules, histone modifications and cytokine signaling molecules (Online 
Supplementary methods). The percentage of cells expressing nuclear T-bet and GATA3 
was assessed in areas of dense lymphocytic infiltration determined by CD4 and CD8 
staining. Cases with >50% cellular staining by both markers were deemed to co-express 
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T-bet and GATA3. For pSTAT3 and pSTAT5, >10% nuclear staining was considered 
positive. Flow cytometry was performed on cell suspensions prepared from tissue 
samples (Online Supplementary methods).  
 
T-cell receptor gene rearrangement analysis 
Polymerase chain reaction (PCR) analysis to determine clonal T-cell receptor beta 
(TRB) and/or gamma (TRG) gene rearrangement was performed using the ‘Biomed-2’ 
primers on DNA extracted from fresh or FFPE GI biopsies, lymph nodes, peripheral 
blood, and bone marrow mononuclear cells, as previously described22.  
 
Next-generation sequencing 
Targeted next-generation sequencing of lesional and matched normal (control) tissue 
samples was performed using a custom panel of 465 cancer-associated genes, as 
previously described23. Variant calling required at least 5% variant allelic fraction (VAF) 
and at least 10 variant reads. Variants with an allele prevalence >0.01% in gnomAD, 
those reported as benign or likely benign in ClinVar, and germline variants present in 
the normal samples or inferred from VAFs were excluded from analysis. Non-
synonymous variants that were not known driver mutations were analyzed by PolyPhen-
2, SIFT, REVEL, and MetaSVM algorithms. Copy number changes were determined 
based on read depths using fragments per kilobase per million mapped reads (FPKM)24 
normalized to a pool of sex-matched control samples. The Fusion and Chromosomal 
Translocation Enumeration and Recovery Algorithm (FACTERA)25 was used to detect 
structural chromosomal alterations, which were confirmed by PCR using breakpoint-
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specific primers and Sanger sequencing of the PCR products (Online Supplementary 
methods).  
 
Fluorescent In-situ hybridization (FISH) analysis 
FISH analysis was performed to assess for SETD2 and JAK2 alterations on FFPE 
tissue sections using custom designed hybridization probes and dual-color break-apart 
probes (Oxford Gene Technologies Inc, Tarrytown, NY), respectively, as previously 
described17,26. Hybridization patterns of at least 100 tumor nuclei were reviewed for 
each probe. Cases were considered to have SETD2 deletion, if the percentage of nuclei 
with SETD2 locus deletion exceeded the cut-off value of 11.2%, and JAK2 
rearrangement, if the frequency of split-signals exceeded the cut-off value of 5.0%. 
 
Results 
Clinical characteristics and patient outcomes 
Ten patients (M:F = 8:2) with ITLPD of the GI tract were identified at the contributing 
centers (cases 1, 2, and 4 were reported previously)11. The clinical features are 
summarized in Table 1. The median age at diagnosis was 45 years (range: 37-64 
years). The ethnicity of 8 patients with available data was: White (n=5), Hispanic (n=2), 
and Asian (n=1). The most common signs and symptoms were diarrhea (70%), weight 
loss (60%), and abdominal pain (50%), with durations ranging from 2 to 16 years prior 
to diagnosis. Two patients lacked GI symptoms, with disease detected incidentally 
during routine colonoscopy and workup for inguinal lymphadenopathy. One patient had 
peptic ulcer disease, H. pylori infection and positive Hepatitis B and C serologies (case 
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9) and one (case 10) had a history of Crohn’s disease. Five patients had been 
previously misdiagnosed as having celiac disease, seronegative and refractory to a 
gluten-free diet, and/or other types of lymphomas. The endoscopy findings included 
mucosal nodularity (70%), scalloping (40%), erythema (40%), decreased duodenal folds 
(30%), and polyps (20%). Common radiographic findings included abdominal 
lymphadenopathy (55%), bowel wall thickening (33%), and dilated bowel loops (33%). 
Biopsy-proven sites of disease included the small intestine (90%), colon (40%), 
stomach (30%), bone marrow (30%, one case only had cytogenetic evidence of 
disease), and inguinal lymph nodes (20%). Seven of 9 (77%) patients received 
therapeutic interventions consisting of steroids and/or chemotherapy; 2 were monitored 
expectantly. Six of 9 (66%) patients are alive with persistent disease and 3 (33%) died; 
one (case 5) due to septicemia and multiorgan failure following chemotherapy-induced 
intestinal perforation 1 year after diagnosis and 2 (cases 4 and 9) due to disease 
transformation 11 and 27 years post-diagnosis.  
 
Morphologic features 
All cases with small intestinal involvement displayed a dense diffuse or nodular infiltrate 
of small-sized lymphocytes in the lamina propria (Figures 1A and 2A), with extension 
into the submucosa noted in a subset. Villous atrophy was observed in 3/9 ITLPDs 
(cases 2, 4, 9; Figure 1B), however the villi were expanded (blunted appearance) 
(Figure 2B) in many cases, and all except one (case 10) showed crypt hyperplasia. The 
lymphocytes had round, ovoid or mildly irregular nuclei, variable fine or coarse 
chromatin, indistinct or small nucleoli, and scant or moderate cytoplasm (Figures 1C 
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and 2C). No significant increase in intraepithelial lymphocytes (IELs) was identified 
(Figures 1B and 2B), although focal lymphocytic infiltration of the epithelium was 
present in 4/9 ITLPDs (cases 1, 2, 4, and 7). Scattered lymphoid aggregates were seen 
in all except one ITLPD (case 5). Sparse, patchy mucosal infiltrates were noted in the 7 
cases with gastric and/or colonic involvement. Mitotic figures and apoptotic cells were 
inconspicuous. No angiocentricity, angiodestruction, ulceration, or necrosis was 
observed. The histopathologic findings of the small intestinal biopsy from one patient 
with large cell transformation, available for review (case 4), were reported previously11.  
 
Immunophenotypic features 
The immunophenotypic profiles of all cases are summarized in Table 2. Four of 10 
(40%) ITLPDs were CD4+ (Figure 1D), 4 (40%) were CD8+ (Figure 2D) and one each 
(10%) was CD4+/CD8+ (“double-positive”) and CD4-/CD8- (“double-negative”). All 
cases analyzed expressed CD2 (Figure 1E) and CD3 (Figures 1F and 2E). Other T-cell 
antigens were expressed by the majority (Figures 1G and 1H), variable downregulation 
or loss of CD5 and/or CD7 was seen in 4/10 cases (2/4 CD4+, 1/4 CD8+, and 1/1 
double-negative). All except one CD8+ case and the CD4-/CD8- case displayed a 
cytotoxic immunophenotype, with TIA-1 expression (Figure 2F) noted in 3/4 cases and 
variable granzyme B (Figure 2G) expression observed in 2/4 CD8+ cases and in the 
CD4-/CD8- case. CD103 expression was detected in 2/4 CD8+ cases (Figure 2H), with 
one also showing partial CD56 expression (case 8) (Figure 2I). The CD4+/CD8+ and 
the CD4-/CD8- cases expressed PD-1. CD20 highlighted mucosal lymphoid follicles, but 
the neoplastic cells were CD20 negative in all ITLPDs. Surface TCRαβ expression was 
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observed in all cases evaluated by flow cytometry and none expressed TCRγδ. All 
analyzed cases were negative for BCL6, CD10, FoxP3, MATK, PD-L1 or CD30, 
however CD30 expression (and acquisition of cytotoxic proteins) was observed, and 
previously reported, upon large cell transformation (case 4)11. The Ki-67 proliferation 
index was low (<5%) in all ITLPDs evaluated (Figure 1J and 2J). 
 
Cell of origin determination 
Since a good correlation between the transcriptional profiles and immunohistochemistry 
for T-bet and GATA3 has been reported in T-cell lymphomas27, we assessed T-bet and 
GATA3 expression by immunohistochemistry to determine the cell of origin of ITLPDs 
(Table 2, Online Supplementary table 1, and Online Supplementary figure 1). The CD4+ 
cases showed heterogeneity with regards to T-bet and GATA3 expression: 1 case each 
was T-bet+ and GATA3+, suggesting T-helper type 1 (Th1) and type 2 (Th2) lineage, 
respectively and 2 cases showed T-bet and GATA3 co-expression - hybrid Th1/Th2 
profile (Figure 1K and 1L). The CD4+/CD8+ ITLPD also co-expressed T-bet and 
GATA3. The CD4-/CD8- and 3/4 (75%) CD8+ cases were GATA3 positive, implying a 
type-2-polarized effector T-cell (Tc2) phenotype and 1 CD8+ case showed T-bet and 
GATA3 co-expression (Figure 2K and 2L). Sequential analysis of 1 CD4+ ITLPD (case 
2) showed a shift from a Th1/Th2 (T-bet and GATA3 co-expression) to Th2 (GATA3) 
phenotype over the course of disease. Double staining for T-bet and GATA3 performed 
in a subset (cases 2, 7, and 8) confirmed distinct T-bet and GATA3 positive as well as 
T-bet and GATA3 co-expressing lymphocytes (data not shown). 
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T-cell receptor gene rearrangement analysis 
Clonal TRB and/or TRG rearrangement products were detected in all ITLPDs. In 
patients with longitudinal testing, similar sized peaks were observed in all samples, 
confirming persistence of the same lymphocytic clone. 
 
Next-generation sequencing analysis 
Targeted sequencing of 20 ITLPD biopsies from 10 patients and 7 matched normal 
samples (cases 1, 2, 4, 7-10) revealed 36 genetic variants, including 29 
nonsynonymous single nucleotide variants, 1 small indel, and 6 structural variants. The 
average on-target coverage was 1059x (range 809x - 1639x). Twenty-three of 36 
alterations were predicted to be pathogenic based on the published literature or 
prediction algorithms, the remaining 13 mutations were classified as variants of 
uncertain significance (Online Supplementary table 2).  
 
The genetic alterations and their expected functional consequences are summarized in 
Table 3. Pathogenic or potentially pathogenic changes were identified in 8/10 (80%) 
ITLPDs. Three of 4 (75%) CD4+ cases and the CD4+/CD8+ and CD4-/CD8- cases 
harbored alterations of JAK-STAT signaling pathway genes. STAT3 SH2 domain 
hotspot mutations (D661Y and S614R) were noted in three cases and one case each 
had a SOCS1 deletion and a STAT3-JAK2 rearrangement. Of note, conventional 
cytogenetic analysis had previously revealed a balanced translocation t(9;17)(p24;q21) 
in the latter case, the breakpoints corresponding to the JAK2 and STAT3 loci, and JAK2 
rearrangement was confirmed by FISH analysis. Concomitant mutations in epigenetic 
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modifier genes (TET2, DNMT3A, and KMT2D) were observed in 4 cases. A missense 
mutation in the cell cycle regulatory gene CDKN2A and a nonsense mutation in 
TNFAIP3 was detected in 1 case each. 
 
Two of the CD8+ ITLPDs exhibited structural chromosome alterations involving the 
interleukin-2 (IL2) gene. One case demonstrated an IL2-RHOH (Ras homolog family 
member H) rearrangement, representing an inversion of chromosome 4, with 
breakpoints occurring in the 3’ untranslated region (3’ UTR) of both IL2 
(chr4:123372863, c.*44) (Figure 3A) and RHOH (chr4:40246032, c.*449) genes. This 
rearrangement did not affect the coding sequence, but resulted in the deletion of a 
portion of the 3’ UTR of IL2, including five of the six AU-rich regulatory elements (AREs, 
AUUUA). The “reciprocal” RHOH-IL2 rearrangement had breakpoints in the 3’ UTR of 
RHOH (chr4:40246006, c.*424) and intron 3 of IL2 (chr4:123373085, c.352-67). Another 
CD8+ case demonstrated a 1.2 Mb deletion on chromosome 4q, beginning 5 base pairs 
downstream of the IL2 stop codon (chr4:123372903, c.*5) (Figure 3D) and ending 6 
kilobases upstream of TNFAIP3 interacting protein 3 (TNIP3) gene (chr4:122154953), 
deleting all regulatory elements from the IL2 3’ UTR. In addition, an inversion, with 
breakpoints in exon 4 of IL2 (chr4:123372912, c.457) and intron 2 of TNIP3 
(chr4:122128556, c.89+9014) was identified (Figure 3D). A missense mutation in the 
minichromosome maintenance complex component 5 (MCM5) gene was also identified 
in this case. The chromosome breakpoints were confirmed in all ITLPD samples with 
structural IL2 alterations via PCR amplification and Sanger sequencing (Figures 3B-3C 
and 3E-3F). No pathogenic mutations or structural abnormalities were observed in two 
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CD8+ ITLPDs (cases 9 and 10), although a variant of uncertain significance was 
observed in one case (Online Supplementary table 2). 
 
Longitudinal analysis of 5 ITLPDs (cases 1, 2, 4, 7, 8) revealed stable mutational 
profiles in 4 ITLPDs. Accrual of mutations over time was noted in 1 CD4+ ITLPD (case 
4). Only a KMT2D frameshift mutation was detected in the first biopsy, obtained shortly 
after diagnosis. Additional mutations were identified at later time points, including a 
missense TP53 mutation prior to disease transformation. Of interest, the first, second, 
and fourth time-point biopsies had shown different chromosome copy number changes 
(reported previously)11, but none of the altered regions corresponded to the loci of 
mutated genes. 
 
Evaluation of the SETD2-H3K36me3 axis  
No SETD2 mutations were observed by NGS analysis and FISH analysis did not detect 
any SETD2 deletions in the cases analyzed. Additionally, no loss of SETD2 protein or 
H3K36me3 was detected by immunohistochemistry and H3K36me2 expression was 
observed in all analyzed cases (Figure 4A-4C, Online Supplementary Table 3). 
 
Evaluation of JAK-STAT pathway activation 
Due to the presence of frequent and recurrent genetic alterations targeting the JAK-
STAT pathway and IL2 genes, we evaluated pSTAT3-Y705 and pSTAT5-Y694 
expression by immunohistochemistry to assess activation of the JAK-STAT signaling 
pathway. All 9 tested cases only showed single scattered or small clusters of nuclear 
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pSTAT3-Y705 and pSTAT5-Y694 positive cells (<10%) in all biopsies (Figure 4E-4F, 
Online Supplementary Table 3).   
   
Discussion 
Despite an increasing awareness of ITLPDs of the GI tract, deciphering their molecular 
pathogenesis and cellular origins has been challenging, in part due to the rarity of these 
disorders. In this study, comprising one of the largest series of cases evaluated, we 
delineate novel genetic alterations, including recurrent mutations and rearrangements, 
suggest cellular origins, and expand the immunophenotypic spectrum of these 
diseases. 
 
The clinical presentations and disease course of our patients were largely congruent 
with previous descriptions6,8–16. Of interest, the ITLPDs were detected incidentally in two 
asymptomatic patients, which has rarely been documented10. A history of Crohn’s 
disease has been reported in some patients with CD8+ ITLPDs12,13, which was also the 
case for one patient in our series. Prior erroneous diagnoses of seronegative, refractory 
celiac disease in a high proportion (55%) of patients, were deemed to be the 
consequence of misinterpretation of the histopathologic changes and incomplete 
laboratory testing. Due to the relatively recent recognition of these disorders, it is not 
surprising that 40% of the ITLPDs in the current study had been previously 
misdiagnosed as aggressive intestinal T-cell lymphomas (EATL and MEITL). Extra-GI 
disease was observed more frequently (40%) in our series than previous reports, and 
transformation to aggressive lymphoma, which is considered rare8,11,15,28, occurred in 
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two patients, including one with a CD8+ ITLPD. These findings emphasize the need for 
comprehensive clinical and laboratory evaluation and long-term follow-up of individuals 
with these disorders. 
 
Next generation sequencing of the ITLPDs revealed genetic alterations in 80% of the 
cases, including mutations in JAK-STAT signaling pathway genes, observed in 75% of 
the CD4+ cases and in the CD4+/CD8+ and CD4-/CD8- cases. The STAT3 D661Y and 
S614R mutations are well-characterized hotspot mutations that impart greater 
hydrophobicity to the SH2 dimerization surface and promote STAT3 nuclear localization 
and activation29. These mutations have been described in myriad lymphoid neoplasms 
and are quite frequent in T-large granular lymphocytic leukemia29. Perry et al. did not 
detect STAT3 SH2 domain hotspot mutations in five cases analyzed by Sanger 
sequencing, although all tested cases were CD8+12. Deletion of SOCS1, a negative 
regulator of the JAK family proteins30, which was seen in a colonic CD4+ ITLPD, is a 
recurrent abnormality in a variety of T-cell lymphomas and more commonly reported in 
mycosis fungoides31. We confirm the STAT3-JAK2 rearrangement to be a recurrent 
event in CD4+ ITLPDs, however, this alteration was only observed in one (25%) of our 
cases compared to 4/5 (80%) cases in the series of Sharma et al15. 
 
Loss-of-function mutations in epigenetic modifier genes (TET2, DNMT3A, KMT2D) 
represented the next most commonly altered gene class, identified in 40% of cases and 
restricted to CD4+, CD4+/CD8+, and CD4-/CD8- cases. Mutations in epigenetic 
modifiers, which are believed to be early events in lymphomagenesis32,33 and known to 
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cooperate with other mutations in fostering neoplastic transformation33,34, have also 
been reported in diverse T-cell malignancies33,35. However, in contrast to other T-cell 
lymphomas36, IDH1/2 mutations were not observed in any ITLPD. Though not recurrent, 
mutations in CDKN2A and TNFAIP3 suggest roles of cell cycle deregulation37 and NF-
κB activation38 in the pathogenesis of at least some ITLPDs.   
 
Structural chromosome alterations recurrently targeting the 3’ UTR of the IL2 gene that 
were identified in 50% of the CD8+ ITLPDs have not been described before. The 
rearrangements and deletions led to the loss of most or all of the regulatory AREs 
involved in mRNA stability. Studies in mitogen-stimulated Jurkat cells have shown that 
deletion of these regulatory elements, which act as binding sites for components of the 
mRNA degradation machinery39, results in a longer half-life of IL2 mRNA40. Whether 
these alterations lead to changes in the cellular localization of the IL2 transcript or affect 
the assembly or composition of protein complexes that modulate activities beyond its 3’ 
UTR-independent functions has not been investigated. An IL2-TNFRSF17 
rearrangement41, resulting from t(4;16)(q26;p13)41, was previously reported in a CD4+ 
ITLPD9. However, in contrast to our cases, the breakpoints in that case mapped to 
intron 3 of IL2 and exon 1 of the B-cell maturation antigen (BCMA) gene, also known as 
tumor necrosis factor receptor superfamily member 17 (TNFRSF17)41. The authors 
detected a chimeric IL2-TNFRSF17 mRNA, but no fusion protein was identified. The 
functional significance of the prior and current IL2 alterations remains unknown. 
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Despite the frequent JAK-STAT pathway gene mutations and structural alteration of the 
IL2 gene, which encodes a key T-cell cytokine that signals via the JAK-STAT pathway42, 
none of the ITLPDs analyzed showed high-level pSTAT3 or pSTAT5 expression. Our 
findings are similar to Perry et al. who also did not observe significant pSTAT3 
expression12, but contrast with those of Sharma et al. who reported pSTAT5 expression 
in three of four cases with STAT3-JAK2 rearrangements15. The reasons for the 
discrepant findings are unclear. It is plausible that the mutations simply augment the 
sensitivity of ITLPDs to cytokine stimulation, enhancing ligand-mediated signaling as 
described in other T-cell lymphomas43 and aberrant IEL proliferations in refractory celiac 
disease type 244 that harbor STAT3 mutations. 
 
On analysis of serial samples, acquisition of additional mutations, including those 
targeting genes involved in the DNA damage response (TP53, POLE) were only 
identified in an ITLPD that transformed to aggressive lymphoma. It is possible that 
ineffective DNA repair mechanisms fueled acquisition of additional mutations and 
complex chromosome changes in this case11. It is unclear if prolonged azathioprine 
therapy played a role in genomic evolution. Nonetheless, this and other cases in our 
series as well as those published previously highlight the futility of genotoxic 
chemotherapeutic agents for treating ITLPDs of the GI tract. The prognostic relevance 
of periodic genetic analysis needs to be assessed in future larger studies.     
 
Our findings indicate that ITLPDs of the GI tract share certain pathogenetic mechanisms 
with other intestinal T-cell lymphomas. Similar to our cohort, mutations in the JAK-STAT 
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pathway genes represent the most frequent alterations in EATL, MEITL, and intestinal 
T-cell lymphoma, NOS17–21. Similarly, loss-of-function mutations in epigenetic modifier 
genes and DNA damage repair genes have also been reported in aggressive intestinal 
T-cell lymphomas17,18. In contrast to EATL and MEITL, however, SETD2 mutations or 
deletions were not seen in any ITLPD and the burden of pathogenic alterations in 
ITLPDs appears lower17,18. 
 
ITLPDs of the GI tract are immunophenotypically heterogeneous diseases. Our study 
revealed a few unique features that are worth highlighting. In addition to CD4+, CD8+, 
and CD4-/CD8- ITLPDs, we describe a CD4+/CD8+ (double-positive) case. Two 
ITLPDs with a similar phenotype were recently reported from the US and China15,45. 
Two of our CD8+ ITLPDs expressed CD103, which has not been documented before. 
Prior sporadic cases of CD103+ ITLPDs have all been of CD4 T-cell lineage10,13. These 
ITLPDs could arise from αE integrin expressing lamina propria T-cells46,  but the 
possibility of activation induced upregulation of CD103 cannot be excluded47,48. Of note, 
one CD103+ CD8+ ITLPD also showed focal CD56 expression. Distinguishing such 
cases from MEITL can be challenging, however, in addition to the clinical presentation 
and course, the presence of small lymphocytes with bland cytomorphology confined to 
the lamina propria, absent MATK expression, and a low Ki-67 index, can help establish 
a diagnosis of ITLPD. Evaluation of SETD2 and H3K36me3 expression can also aid in 
differentiating ITLPDs from MEITL, which frequently show loss of SETD2 and H3K36 
trimethylation17.  
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ITLPDs of the GI tract are thought to originate from mucosal T-cells, but the cell of origin 
of different disease subsets has not been clarified. Absence of FoxP3 and T-follicular 
helper (TFH) cell markers in the current and previously reported CD4+ ITLPDs11,16 
argues against their derivation from regulatory T-cells or TFH cells. Based on 
expression of T-bet and GATA3, which are transcription factors regulating CD4+ Th1 vs. 
Th2 cell fate decisions, the CD4+ and CD4+/CD8+ ITLPDs in our series displayed Th1, 
Th2, or hybrid Th1/2 profiles. It is not known if ITLPDs with the latter profile develop 
directly from naïve T-cells into bifunctional mucosal Th1/2 cells, similar to those 
described in primary immune responses against parasites, which help dampen 
inflammation49, or derive from Th1 or Th2 cells that have undergone cytokine mediated 
reprogramming to acquire a Th1/Th2 phenotype, with concomitant production of Th1 
and Th2 cytokines50. The phenotypic shift from a Th1/Th2 to Th2 profile over time, 
observed in one CD4+ case, suggests lineage (and possibly functional) plasticity of at 
least a subset of ITLPDs. The majority of the CD8+ cases and the CD4-/CD8- ITLPD 
displayed a Tc2 phenotype51. Besides orchestrating diverse functions in CD4+ T-helper 
cells, GATA3 also regulates the activation, homeostasis, and cytolytic activity of CD8+ 
T-cells52. The significance of T-bet/GATA3 co-expression in CD8+ ITLPDs is unknown. 
It must be pointed out that despite the reported concordance between the transcriptional 
and protein expression profiles of T-bet and GATA3 in certain T-cell lymphomas27, the 
definitive lineage (and function) of neoplastic T-cells cannot be ascertained based on 
the expression of single lineage-associated transcription factors. Cytokine profiling and 
in vitro functional studies are awaited for confirmation of our observations. Contrary to 
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observations in PTCL, NOS27,53,54, however, an inferior prognostic impact of GATA3 
expression was not apparent in our series of ITLPDs. 
 
In conclusion, our study reveals considerable immunophenotypic and genetic 
heterogeneity of GI ITLPDs. We describe recurrent and novel genetic abnormalities in 
different immunophenotypic subtypes of GI ITLPDs that implicate deregulated cytokine 
signaling and epigenetic alterations in disease pathogenesis. It is hoped that future 
unbiased interrogation of ITLPD genomes and transcriptomes as well as mechanistic 
studies will help clarify the cell of origin and the functional consequences of the 
underlying genetic aberrations in these rare disorders, opening the door for targeted, 
less toxic and more effective therapies.  
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Case Age Sex Eth 
 
Presenting 
signs & 
symptoms 
Duration 
of 
symptoms 
prior to 
diagnosis 
(years) 
Other 
conditions 
Prior 
diagnosis  
Endoscopic 
findings 
Radiographic 
findings 
Sites of 
involvement†  
Ann Arbor 
stage (at 
diagnosis) 
Treatment 
Outcome 
(Cause 
of death) 
1* 53 M W 
Diarrhea, 
weight 
loss, 
night 
sweats 
16 None Celiac disease 
Mucosal 
nodularity, 
scalloping, 
decreased 
duodenal folds, 
erythema 
Mild 
mesenteric 
LAD, mild 
FDG activity 
Duodenum, 
jejunum, 
ileum 
IEB Bud AWD, 9 years 
2* 50 F W 
Diarrhea, 
weight 
loss, 
abd pain, 
fatigue 
3 None Celiac disease 
Mucosal 
nodularity, 
Scalloping 
SB wall 
thickening and 
dilation  
Duodenum,  
ileum, 
appendix, 
colon, 
stomach, BM‡ 
IEB Pral, Romi, Bud 
AWD, 
7 years 
3 64 F NA No GI 
symptoms 0 NA None 
Sessile polyp in 
colon NA Colon NA NA NA 
4*† 37 M W Diarrhea, 
weight loss 2 None 
Celiac 
disease 
Mucosal 
nodularity, 
Scalloping 
Normal 
Duodenum, 
ileum, 
colon, 
stomach  
IEB Bud, Pred, Aza 
D, 11 
years 
(Large 
cell trans) 
5 62 M H Diarrhea 
weight loss NA NA 
Celiac 
disease, 
EATL 
Mucosal 
nodularity, 
scalloping, 
mosaic pattern, 
increased 
vascularity, 
ulcer 
SB and LB 
dilation 
Duodenum, 
jejunum, 
inguinal LN 
IEB CP, Dox, VCR, Pred 
D, 1 year 
(SB perf) 
6 41 M NA No GI 
symptoms 0 MG None 
 Polypoid ileal 
lesions 
Mesenteric 
and 
iliac LAD 
Ileum, colon, 
stomach, 
inguinal LN, 
BM 
IVE None AWD,  1 year 
7 38 M W 
Diarrhea, 
abd pain, 
vomiting 
5 Lyme disease EATL 
Mucosal 
nodularity, 
decreased 
duodenal folds, 
gastric 
erythema 
SB wall 
thickening, 
intuss, 
mesenteric 
LAD 
Duodenum, 
jejunum, 
ileum, colon 
IE None AWD, 21 years 
8 38 M H 
Diarrhea, 
weight 
loss, 
abd pain  
5 CHD MEITL 
Mucosal 
nodularity, 
erythema, 
friability 
Mesenteric 
and 
retroperitoneal 
LAD, incr 
FDG activity 
Duodenum, 
ileum, colon IEB 
CP, Dox, 
VCR, Bud, 
Pred, 
Etop, 
AGS67E 
AWD, 
7 years 
 9† 41 M A Abd pain 3 
PUD, H. 
pylori,  
viral hep 
(B & C)  
Atyp 
lymphoid 
infiltrate, 
favor MZL  
Mucosal 
nodularity,  
decreased 
duodenal folds 
Abd LAD, mild 
FDG activity, 
splenomegaly 
Duodenum, 
stomach,  
BM 
IE 
IFN, CP, 
Dox, VCR, 
Pred, Gem 
D, 27 
years 
(Large 
cell trans)  
10 49 M W 
Diarrhea 
weight 
loss, 
abd pain 
5 Crohn’s disease§ 
Celiac 
disease, 
EATL 
Flattened SB 
mucosa, 
 gastric 
erythema  
Mild SB wall 
thickening and 
dilation, partial 
SB 
obstruction 
Duodenum, 
jejunum  IEB 
CP, Dox, 
VCR, 
Pred, Mes, 
Aza 
AWD, 
19 years 
   
Table 1: Clinical characteristics of gastrointestinal ITLPD patients 
A, Asian; abd, abdominal; AGS67E, Anti-CD37 monoclonal antibody AGS67E; AWD, alive with disease; Aza, Azathioprine; BM, bone marrow; Bud, 
budesonide; CHD, congenital heart disease; CP, cyclophosphamide; D, dead; Dox, doxorubicin; EATL, enteropathy associated T-cell lymphoma; 
Eth, ethnicity; Etop, Etoposide; F, female; FDG, fluorodeoxyglucose; Gem, Gemcitabine; GI, gastrointestinal; H, Hispanic; hep, hepatitis; IFN, 
Interferon; incr, increased; intuss, intussusception; LAD, lymphadenopathy; LB, large bowel; LN, lymph node; M, male; MEITL, monomorphic 
epitheliotropic intestinal T-cell lymphoma; Mes, mesalamine; MG, monoclonal gammopathy; MZL, marginal zone lymphoma; NA, not available; perf, 
perforation; PUD, peptic ulcer disease; Pral, Pralatrexate; Pred, Prednisone; Romi, Romidepsin; SB, small bowel; trans, transformation; VCR; 
vincristine; W, White 
*Previously published cases. 
†Findings prior to large cell transformation. 
‡ Bone marrow involvement was detected by cytogenetic analysis; there was no morphologic or immunophenotypic evidence of disease and TCRβ 
PCR showed polyclonal products. 
§ Biopsies diagnosed as Crohn’s disease were not reviewed by authors.  
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Case CD4 CD8 CD2 CD3 CD5 CD7 TIA-1 GrzB Perf CD103 CD56 BCL6 CD10 PD-1 PD-L1 FoxP3 MATK TCRαβ TCRγδ CD30 
Ki67 
(%) 
T-bet GATA3 
1* + - + + -/+ - - - - - - - - - - - - + - - <5 + - 
2* + - + + + + - - - - - - - - - - - + - - <5 + + 
3 + - NA + + + - - - - - NA NA NA - NA - + - - NA - + 
4*† + - + + +/- - - - - - - - - - - - - +/- - - <5 + + 
5 + + + + + + - - - - - - - + - - - + - - <5 + + 
6 - - + + + -/+ + -/+ NA - - - - + NA - NA + - - <5 - + 
7 - + + + + + - - - + - - - - - - - + - - <5 - + 
8 - + + + + +
 
+ +/- - + +/- - - - - - - + - - <5 + + 
9† - + + + - -/+ + - - - - - - - - - - + - - <5 - + 
10 - + + + + + + + - - - - - - - - NA + - - <5 - + 
TOTAL 5/10 (50%) 
4/10 
(40%) 
9/9 
(100%) 
10/10 
(100%) 
8/10 
(80%) 
6/10 
(60%) 
4/10 
(40%) 
2/9 
(22%) 
0/9 
(0%) 
2/10 
(20%) 
1/10 
(10%) 
0/9 
(0%) 
0/9 
(0%) 
2/9 
(22%) 
0/9 
(0%) 
0/9 
(0%) 
0/8 
(0%) 
10/10 
(100%) 
0/10 
(0%) 
0/10 
(0%)  
5/10 
(50%) 
9/10 
(90%) 
CD4+ 4/4 (100%) 
0/4 
(0%) 
3/3 
(100%) 
4/4 
(100%) 
3/4 
(75%) 
2/4 
(50%) 
0/4 
(0%) 
0/4 
(0%) 
0/4 
(0%) 
0/4 
(0%) 
0/4 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/4 
(0%) 
0/3 
(0%) 
0/4 
(0%) 
4/4 
(100%) 
0/4 
(0%) 
0/4 
(0%)  
3/4 
(75%) 
3/4 
(75%) 
DP 1/1 (100%) 
1/1 
(100%) 
1/1 
(100%) 
1/1 
(100%) 
1/1 
(100%) 
1/1 
(100%) 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
1/1 
(100%) 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
1/1 
(100%) 
0/1 
(0%) 
0/1 
(0%)  
1/1 
(100%) 
1/1 
(100%) 
DN 0/1 (0%) 
0/1 
(0%) 
1/1 
(100%) 
1/1 
(100%) 
1/1 
(100%) 
0/1 
(0%) 
1/1 
(100%) 
0/1 
(0%) NA 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
0/1 
(0%) 
1/1 
(100%) NA 
0/1 
(0%) NA 
1/1 
(100%) 
0/1 
(0%) 
0/1 
(0%)  
0/1 
(0%) 
1/1 
(100%) 
CD8+ 0/4 (0%) 
4/4 
(100%) 
4/4 
(100%) 
4/4 
(100%) 
3/4 
(75%) 
3/4 
(75%) 
3/4 
(75%) 
2/4 
(50%) 
0/4 
(0%) 
2/4 
(50%) 
1/4 
(25%) 
0/4 
(0%) 
0/4 
(0%) 
0/4 
(0%) 
0/4 
(0%) 
0/4 
(0%) 
0/3 
(0%) 
4/4 
(100%) 
0/4 
(0%) 
0/4 
(0%)  
1/4 
(25%) 
4/4 
(100%) 
  
Table 2: Immunophenotypic characteristics of gastrointestinal ITLPDs 
+, positive; -, negative; DN, double-negative; DP, double-positive; GrzB, Granzyme B; NA, not available; Perf, perforin; TCRαβ, T-cell receptor 
alpha-beta; TCRγδ, T-cell receptor gamma-delta 
*Previously published cases 
†Findings at diagnosis prior to large cell transformation 
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Case
 
Phenotype
 
Time Point 
(years 
following 
diagnosis)
 
Genetic alterations
 
Predicted Functional Consequence
 
1 CD4+ 
2.5 STAT3 (c.1981G>T, p. D661Y) TET2 (c.2457T>G, p. Y819*) 
Activation of JAK-STAT pathway 
Altered DNA methylation 
7.9 STAT3 (c.1981G>T, p. D661Y) TET2 (c.2457T>G, p. Y819*) 
Activation of JAK-STAT pathway 
Altered DNA methylation 
2 CD4+ 
0 STAT3-JAK2 rearrangement TNFAIP3 (c.857T>G, p.L286*) 
Activation of JAK-STAT pathway 
Activation of NF-κB pathway 
2.2 STAT3-JAK2 rearrangement TNFAIP3 (c.857T>G, p.L286*) 
Activation of JAK-STAT pathway 
Activation of NF-κB pathway 
6.4 STAT3-JAK2 rearrangement TNFAIP3 (c.857T>G, p.L286*) 
Activation of JAK-STAT pathway 
Activation of NF-κB pathway 
3 CD4+ 0 SOCS1 deletion Activation of JAK-STAT pathway 
4 CD4+ 
0.5 KMT2D (c.13105_13108del, p.L4369fs) Altered histone modification 
7.4 KMT2D (c.13105_13108del, p.L4369fs) DIS3
 (c.1115T>C, p.L372P) 
Altered histone modification 
Altered RNA processing and decay 
11.5 
KMT2D (c.13105_13108del, p.L4369fs)   
DIS3
 (c.1115T>C, p.L372P) 
MAPK1 (c.965A>T, p.E322V) 
TP53 (c.743G>A, p.R248Q) 
POLE
 (c.4090C>T, p.R1364C) 
Altered histone modification 
Altered RNA processing and decay  
Activation of RAS-RAF-MAPK pathway 
DNA repair/ cell cycle dysregulation 
Altered DNA repair and replication 
11.7† 
KMT2D (c.13105_13108del, p.L4369fs)   
DIS3
 (c.1115T>C, p.L372P) 
MAPK1 (c.965A>T, p.E322V) 
TP53 (c.743G>A, p.R248Q) 
POLE
 (c.4090C>T, p.R1364C) 
TET2 (c.2725C>T, p.Q909*) 
SMAD4 (c.404G>A, p.R135Q) 
SF3B1 (c.2584G>A, p.E862K) 
Altered histone modification 
Altered RNA processing and decay 
Activation of RAS-RAF-MAPK pathway 
DNA repair/ cell cycle dysregulation 
Altered DNA repair and replication 
Altered DNA methylation 
Activation of TGF-β pathway 
Altered RNA splicing 
5 CD4+/CD8+ 0 
STAT3 (c.1842C>G, p.S614R) 
DNMT3A (c.2116G>T, p.G706W) 
CDKN2A (c.322G>A, p.D108N) 
Activation of JAK-STAT pathway 
Altered DNA methylation 
Cell cycle checkpoint (G1-to-S) dysregulation 
 6 CD4-/CD8- 0 STAT3 (c.1840A>C, p.S614R) KMT2D (c.9415C>G, p.P3139A) 
Activation of JAK-STAT pathway 
Altered histone modification 
7 CD8+  
0 IL2-RHOH rearrangement‡ Unknown 
3.9 IL2-RHOH rearrangement‡ Unknown 
6.1 IL2-RHOH rearrangement‡ Unknown 
8 CD8+  
0 IL2 3’ UTR deletion
‡
, IL2-TNIP3 rearrangement‡ 
MCM5 (c.2080A>T, p.I694F) 
Unknown 
Cell cycle dysregulation 
4.3 IL2 3’ UTR deletion
‡
, IL2-TNIP3 rearrangement‡ 
MCM5 (c.2080A>T, p.I694F) 
Unknown 
Cell cycle dysregulation 
6.4  IL2 3’ UTR deletion
‡
, IL2-TNIP3 rearrangement‡ 
MCM5 (c.2080A>T, p.I694F) 
Unknown 
Cell cycle dysregulation 
9 CD8+  14 None identified NA 
10 CD8+  10.8 None identified NA 
Table 3: Genetic alterations in gastrointestinal ITLPDs 
NA, not applicable 
† Large cell transformation 
‡ Confirmed by breakpoint specific PCR and Sanger sequencing 
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Figure Legends 
Figure 1 - Morphologic and immunophenotypic features of CD4+ ITLPD of the GI tract.   
(A) A duodenal biopsy (case 2) shows a dense lymphocytic infiltrate within the lamina propria, 
as well as villous atrophy and crypt hyperplasia. (B) There is no increase in intraepithelial 
lymphocytes. (C) The lymphocytes are small and have round to ovoid nuclei, fine chromatin, 
indistinct or small nucleoli, and moderate pale pink cytoplasm. The lymphocytes express (D) 
CD4, (E) CD2, (F) CD3, (G) CD5, and (H) CD7. (I) The neoplastic cells do not express CD103. 
(J) The Ki-67 proliferation index is low (<5%). The majority of cells are (K) T-bet+, however, 
50% also express (L) GATA3.  
 
Figure 2 - Morphologic and immunophenotypic features of CD8+ ITLPD of the GI tract.   
(A) An ileal biopsy (case 8) shows a dense mucosal lymphocytic infiltrate expanding the lamina 
propria and widening the villi, no villous atrophy is present but the crypts are hyperplastic. (B) 
Small clusters of lymphocytes are seen within the villus epithelium along the lateral edges, there 
is no increase in intraepithelial lymphocytes. (C) The lymphocytes are small and have round or 
oval nuclei, condensed chromatin, indistinct nucleoli, and scant to moderate clear or pale pink 
cytoplasm. The lymphocytes express (D) CD8 and (E) CD3. Most of the cells express the 
cytotoxic marker (F) TIA1 and (G) Granzyme B is expressed by a subset.  (H) The lymphocytes 
are CD103+ and a subset expresses (I) CD56.  (J) The Ki-67 proliferation index is low (<5%). 
The majority of cells express (K) GATA3, but 60% also show (L) T-bet expression. 
 
Figure 3: Structural chromosome alterations of the IL2 gene in CD8+ ITLPDs 
In case 7, (A) two chromosome breaks were detected as a consequence of a rearrangement 
involving the 3’ UTR of IL2 and 3’ UTR of RHOH (“IL2-RHOH”) and a reciprocal rearrangement 
involving intron 3 of IL2 and the 3’ UTR of RHOH (“RHOH-IL2”). (B) Pile-up of a subset of reads 
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mapping to the IL2-RHOH rearrangement. (C) Sanger sequencing validation of the fusion 
breakpoints. 
 
In case 8, (D) two chromosome breaks were observed due to a 1.2 Mb deletion spanning the 
majority of the 3’ UTR of IL2 and a portion of the intergenic region between IL2 and TNIP3 (“IL2 
3’ UTR del”) and an inversion involving exon 4 of IL2 and intron 2 of TNIP3 (“IL2-TNIP3”). (E) 
Pile-up of a subset of reads mapping to the IL2 3’ UTR deletion. (F) Sanger sequencing 
validation of the deletion breakpoints.  
† Chromosome position based on assembly GRCh37.p13 
 
Figure 4: Analysis of the SETD2-H3K36me3 axis and JAK-STAT pathway activation.   
IHC analysis of a CD4+ ITLPD with STAT3-JAK2 rearrangement (case 2) shows preserved (A) 
SETD2, (B) H3K36me2, and (C) H3K36me3 protein expression. The lymphocytes express (D) 
CD4. Only a few scattered (E) pSTAT3-Y705 positive and (F) pSTAT5-Y694 positive cells are 
noted (comprising <10% of the neoplastic lymphocytes). 
 




Supplementary Methods 
Immunohistochemistry 
Immunohistochemical (IHC) staining was performed using the following primary antibodies: 
CD3, CD5, CD8, CD20 and CD30 (DAKO, Carpinteria, CA); CD2, CD7, CD25 and CD56, 
(Vector, Burlingame, CA); CD4 (BioGenex, San Ramon, CA); TCRγ (ThermoFisher, Waltham, 
MA); perforin (Novocastra, Newcastle Upon Tyne, UK); granzyme-B (Chemicon, Temecula, 
CA); T-cell intracellular antigen-1 (TIA-1) (Beckman Coulter, Fullerton, CA); Ki-67 (Ventana, 
Tucson, AZ); PD1 (Cell Marque, Rocklin, CA); CD103, FoxP3, H3K36me3, H3K36me2 (Abcam, 
Cambridge, MA), GATA3 (Biocare Medical, Pacheco, CA), T-bet, p-STAT3(Tyr705)(clone 
D3A7) (Cell Signaling Technologies, Danvers, MA), p-STAT5(Tyr694/9)(clone Y694/99) 
(Advantex BioReagents, Houston, TX), MATK(LSK)(clone H-1) (Santa Cruz Biotechnology, 
Dallas, TX) and SETD2 (Sigma, Darmstadt, Germany).  Staining for pSTAT5 was performed on 
a Benchmark Ultra autostainer (Ventana). After heat-induced epitope retrieval (Tris based pH = 
9.0), slides were incubated with the antibody (1:50 dilution) for 32 minutes at 37°C; Optiview 
DAB kit  (Ventana) was used for visualization. Staining for pSTAT3 was performed on a 
Discovery Ultra autostainer (Ventana). After heat-induced epitope retrieval (Tris based pH = 
9.0), slides were incubated with antibody (1:25 dilution) for 2 hours at room temperature; 
ChromoMap DAB kit (Ventana) was used for visualization. MATK staining was performed on a 
Bond Max autostainer (Leica Biosystems, Bannockburn, IL, USA). After heat-induced epitope 
retrieval (EDTA based pH = 9.0), slides were incubated with antibody (dilution of 1:200) for 15 
minutes; Bond Polymer Refine detection kit (Leica) was used for visualization. For SETD2 and 
H3K36, IHC was performed manually after heat-induced antigen retrieval (Tris/EDTA pH = 9.0) 
as previously described17. All other IHC staining was performed according to standard protocols 
on a Bond III autostainer (Leica) after online-automated heat epitope induced retrieval and the 
Bond Polymer Refine detection kit was used for visualization.  
 
Flow cytometry 
Four or eight color flow cytometry was performed on cell suspensions prepared from tissue 
samples (FACScan; Becton Dickinson, San Diego, CA) and data were analyzed using FCS 
Express software (De Novo Software, Los Angeles, CA) according to standard procedures. The 
antigens evaluated included CD45, CD2, CD3 (cytoplasmic and surface), CD4, CD5, CD7, CD8, 
CD30, CD56, CD20, CD25, CD43, CD103, PD1, TCRαβ and TCRγδ. 
 
Validation of chromosomal structural alterations  
PCR amplification of the DNA breakpoints and Sanger sequencing was performed on the tumor 
and matched normal samples.  M13-tailed case-specific primers were designed to span the 
identified breakpoints. PCR was performed using 50 ng sample DNA, 30 ng of each specific 
primer, and Platinum Taq High Fidelity DNA polymerase (Invitrogen, ThermoFisher Scientific, 
Pittsburgh, PA). Thermal cycling conditions were one cycle at 94 C for five minutes; followed by 
35 cycles at 94 C for 60s, 55 C for 90s, 68 C for 60s; followed by 68 C for 5 min. Products were 
used as templates for bidirectional BigDyeTerminator V1.1 Sanger sequencing (Applied 
Biosystems, ThermoFisher Scientific, Pittsburgh, PA).   
 
  
Supplementary Tables 
 
Supplementary Table 1: Quantification of T-bet and GATA3 expression. 
 
Case Phenotype T-bet (% positive) 
GATA3 
(% positive) 
1 CD4+ 100% 20% 
2 CD4+ 100% 50% 
3 CD4+ 20% 100% 
4 CD4+ 100% 100% 
5 CD4+/CD8+ 50% 100% 
6 CD4-/CD8- 5% 100% 
7 CD8+ 20% 100% 
8 CD8+ 60% 100% 
9 CD8+ 10% 100% 
10 CD8+ 20% 100% 
 
 
  
Supplementary Table 2: Variants of Uncertain Significance 
 
Case Gene Transcript Chrm Position Total Reads 
Alt 
Reads 
Ref 
Base 
Alt 
Base 
AA 
Change 
Base 
Change 
4 FAT1 NM_005245 4 187628173 601 45 G A R937X c.2809C>T 
4 FOXL2 NM_023067 3 138665048 213 16 C G A173P c.517G>C 
4 KAT6A NM_001099412 8 41790108 1397 109 C T R1877H c.5630G>A 
4 KDM5C NM_004187 X 53223826 626 122 G A S1178L c.3533C>T 
4 KDM5C NM_004187 X 53223844 587 119 G T P1172H c.3515C>A 
4 KMT2D NM_003482 12 49415596 276 24 A C C5527W c.16581T>G 
4 RBM10 NM_001204468 X 47032564 291 53 G A R222Q c.665G>A 
6 MED12 NM_005120 X 70339981 684 117 G A E172K c.514G>A 
6 TET2 NM_001127208 4 106164741 438 130 C G S1203R c.3609C>G 
7 PDGFRA NM_006206 4 55143621 491 26 C A S618Y c.1853C>A 
7 POLE NM_006231 12 133256236 488 25 G T P142Q c.425C>A 
8 FAT1 NM_005245 4 187524362 737 42 C T R3773H c.11318G>A 
9 ROS1 NM_002944 6 117714432 1146 253 G A P406L c.1217C>T 
 
  
Supplementary Table 3: SETD2-H3K36me3 and pSTAT3/pSTAT5  
Immunohistochemical Analysis 
 
Case SETD2 FISH 
SETD2 
IHC H3K36me2 H3K36me3 
pSTAT3 
(Y705) 
pSTAT5 
(Y694) 
1 - + + + - - 
2 - + + + - - 
3 NP NP NP NP - - 
4 - + + + - - 
5 NP NP NP NP - - 
6 - + + + - NP 
7 - + + + - - 
8 - + + + - - 
9 - + + + - - 
10 NP NP NP NP NP NP 
TOTAL 0/7 0% 
7/7 
(100%) 
7/7 
(100%) 
7/7 
(100%) 
0/9 
(0%) 
0/8 
(0%) 
CD4+ 0/3 (0%) 
3/3 
(100%) 
3/3 
(100%) 
3/3 
(100%) 
0/4 
(0%) 
0/4 
(0%) 
DP NP NP NP NP 0/1 (0%) 
0/1 
(0%) 
DN 0/1 (0%) 
1/1 
(100%) 
1/1 
(100%) 
1/1 
(100%) 
0/1 
(0%) NP 
CD8+ 0/3 (0%) 
3/3 
(100%) 
3/3 
(100%) 
3/3 
(100%) 
0/3 
(0%) 
0/3 
(0%) 
 
 
  
+, positive; -, negative; DN, Double-negative; DP, Double-positive; 
NP, Not performed 
Supplementary Figures 
 
Supplementary Figure 1: T-bet and GATA3 immunohistochemistry. 
 
 
 
Case 1 is positive for (A) CD4 and negative for (B) CD8. (C) T-bet is expressed by the majority and (D) GATA3 
is expressed by 20% of cells.  
 
Case 9 is negative for (E) CD4 and positive for (F) CD8. (G) GATA3 is expressed by virtually all the cells and (H) 
T-bet is expressed by 10% of cells. 
